Literature DB >> 15786634

Use of the artificial iris implant in patients with aniridia.

Marlane J Brown1, David R Hardten, Kimberly Knish.   

Abstract

BACKGROUND: Aniridia (or partial aniridia) often occurs as a result of a penetrating ocular trauma. This condition may cause symptoms including glare, light sensitivity, reduced vision, and asymmetric appearance. Options for these patients include specialty contact lenses, corneal tattooing, and artificial iris implants. This article details six patients who experienced penetrating trauma with significant iris tissue loss and who chose to have an artificial iris implant. CASE REPORTS: Six patients with traumatic aniridia were enrolled in a single-site, single-surgeon study. They were followed for one year postoperatively. All six were complex cases that had multiple eye problems, such as aphakia, corneal scarring, corneal graft rejection, and retinal detachment. All participants were male. All patients experienced decrease in glare and light sensitivity following artificial iris implant surgery. Two experienced improved best-corrected vision (BCVA). All six patients felt the cosmetic appearance of their affected eye improved.
CONCLUSIONS: The artificial iris device provides an effective means of treating traumatic aniridia. Optometrists often work with patients who have experienced a penetrating ocular trauma, with complete or partial aniridia as a complication. In cases in which nonsurgical means are not effective in returning the patient to comfort and productivity, an artificial iris implant should be considered.

Entities:  

Mesh:

Year:  2005        PMID: 15786634     DOI: 10.1016/s1529-1839(05)70280-3

Source DB:  PubMed          Journal:  Optometry        ISSN: 1558-1527


  1 in total

1.  Simultaneous correction of post-traumatic aphakia and aniridia with the use of artificial iris and IOL implantation.

Authors:  Cesare Forlini; Matteo Forlini; Robert Rejdak; Agata Prokopiuk; Oxana Levkina; Adriana Bratu; Paolo Rossini; Perfecto R Cagampang; Gian Maria Cavallini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-01-17       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.